Method for treating malignancy and autoimmune disorders in humans using tac antibodies
US7094404B1 · kind B1 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Aug 22, 2006 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.